graft vs host disease

Summary

Summary: The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.

Top Publications

  1. Jacobson C, Turki A, McDonough S, Stevenson K, Kim H, Kao G, et al. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:565-74 pubmed publisher
    ..There is no increased risk of relapse, suggesting that graft-versus-leukemia activity is maintained. Early reconstitution of B cells and NK cells may, in part, account for these findings...
  2. Ye H, Lv M, Zhao X, Zhao X, Huang X. Plasma level of lipopolysaccharide-binding protein is indicative of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2012;95:680-8 pubmed publisher
    ..There was no correlation between LBP level and the site of aGVHD. In conclusion, our study demonstrated that an elevated LBP level of >15000 ng/ml may serve as a biomarker for the prediction and monitoring of aGVHD...
  3. Kumar A, Mhaskar A, Reljic T, Mhaskar R, Kharfan Dabaja M, Anasetti C, et al. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia. 2012;26:582-8 pubmed publisher
    ..75-2.69; P = 0.28). Use of ATG was not associated with significant reduction in non-relapse mortality (RR = 0.74; 95% CI, 0.53-1.03; P = 0.08). Future trials with adequate sample size are required to provide more definitive answers...
  4. Miyagawa F, Okiyama N, Villarroel V, Katz S. Identification of CD3+CD4-CD8- T cells as potential regulatory cells in an experimental murine model of graft-versus-host skin disease (GVHD). J Invest Dermatol. 2013;133:2538-2545 pubmed publisher
    ..These findings suggest that DN T cells that accumulate in double Tg mice have regulatory functions and may have a role in the maintenance of peripheral tolerance in vivo. ..
  5. Kwan W, Hashimoto D, Paz Artal E, Ostrow K, Greter M, Raedler H, et al. Antigen-presenting cell-derived complement modulates graft-versus-host disease. J Clin Invest. 2012;122:2234-8 pubmed publisher
    ..Our data mechanistically link APC-derived complement to T cell-mediated GvHD and support complement inhibition as a therapeutic strategy for GvHD in humans...
  6. Blazar B, Murphy W, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12:443-58 pubmed publisher
    ..This Review highlights the recent advances in understanding the pathophysiology of GVHD and its treatment, with a focus on manipulations of the immune system that are amenable to clinical application...
  7. Robb R, Hill G. The interferon-dependent orchestration of innate and adaptive immunity after transplantation. Blood. 2012;119:5351-8 pubmed publisher
    ..This Perspective discusses the current literature on the IFNs and their potential modulation within clinical transplantation, focusing particularly on enhancing the therapeutic GVL effects...
  8. Hymes S, Alousi A, Cowen E. Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease. J Am Acad Dermatol. 2012;66:515.e1-18; quiz 533-4 pubmed publisher
    ..Part II discusses the topical, physical, and systemic treatment options available to patients with graft-versus-host disease...
  9. Ngoma A, Ikeda K, Hashimoto Y, Mochizuki K, Takahashi H, Sano H, et al. Impaired regulatory T cell reconstitution in patients with acute graft-versus-host disease and cytomegalovirus infection after allogeneic bone marrow transplantation. Int J Hematol. 2012;95:86-94 pubmed publisher
    ..05). Thus, impaired reconstitution of Tregs may be associated with aGVHD and CMV infection. Moreover, imbalance of Tregs and CD8? cells may play a role in aGVHD tissue...
  10. Ferrara J, Harris A, Greenson J, Braun T, Holler E, Teshima T, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118:6702-8 pubmed publisher
    ..001). REG3? is a plasma biomarker of GI GVHD that can be combined with clinical stage and histologic grade to improve risk stratification of patients...

Detail Information

Publications62

  1. Jacobson C, Turki A, McDonough S, Stevenson K, Kim H, Kao G, et al. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:565-74 pubmed publisher
    ..There is no increased risk of relapse, suggesting that graft-versus-leukemia activity is maintained. Early reconstitution of B cells and NK cells may, in part, account for these findings...
  2. Ye H, Lv M, Zhao X, Zhao X, Huang X. Plasma level of lipopolysaccharide-binding protein is indicative of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2012;95:680-8 pubmed publisher
    ..There was no correlation between LBP level and the site of aGVHD. In conclusion, our study demonstrated that an elevated LBP level of >15000 ng/ml may serve as a biomarker for the prediction and monitoring of aGVHD...
  3. Kumar A, Mhaskar A, Reljic T, Mhaskar R, Kharfan Dabaja M, Anasetti C, et al. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia. 2012;26:582-8 pubmed publisher
    ..75-2.69; P = 0.28). Use of ATG was not associated with significant reduction in non-relapse mortality (RR = 0.74; 95% CI, 0.53-1.03; P = 0.08). Future trials with adequate sample size are required to provide more definitive answers...
  4. Miyagawa F, Okiyama N, Villarroel V, Katz S. Identification of CD3+CD4-CD8- T cells as potential regulatory cells in an experimental murine model of graft-versus-host skin disease (GVHD). J Invest Dermatol. 2013;133:2538-2545 pubmed publisher
    ..These findings suggest that DN T cells that accumulate in double Tg mice have regulatory functions and may have a role in the maintenance of peripheral tolerance in vivo. ..
  5. Kwan W, Hashimoto D, Paz Artal E, Ostrow K, Greter M, Raedler H, et al. Antigen-presenting cell-derived complement modulates graft-versus-host disease. J Clin Invest. 2012;122:2234-8 pubmed publisher
    ..Our data mechanistically link APC-derived complement to T cell-mediated GvHD and support complement inhibition as a therapeutic strategy for GvHD in humans...
  6. Blazar B, Murphy W, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12:443-58 pubmed publisher
    ..This Review highlights the recent advances in understanding the pathophysiology of GVHD and its treatment, with a focus on manipulations of the immune system that are amenable to clinical application...
  7. Robb R, Hill G. The interferon-dependent orchestration of innate and adaptive immunity after transplantation. Blood. 2012;119:5351-8 pubmed publisher
    ..This Perspective discusses the current literature on the IFNs and their potential modulation within clinical transplantation, focusing particularly on enhancing the therapeutic GVL effects...
  8. Hymes S, Alousi A, Cowen E. Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease. J Am Acad Dermatol. 2012;66:515.e1-18; quiz 533-4 pubmed publisher
    ..Part II discusses the topical, physical, and systemic treatment options available to patients with graft-versus-host disease...
  9. Ngoma A, Ikeda K, Hashimoto Y, Mochizuki K, Takahashi H, Sano H, et al. Impaired regulatory T cell reconstitution in patients with acute graft-versus-host disease and cytomegalovirus infection after allogeneic bone marrow transplantation. Int J Hematol. 2012;95:86-94 pubmed publisher
    ..05). Thus, impaired reconstitution of Tregs may be associated with aGVHD and CMV infection. Moreover, imbalance of Tregs and CD8? cells may play a role in aGVHD tissue...
  10. Ferrara J, Harris A, Greenson J, Braun T, Holler E, Teshima T, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118:6702-8 pubmed publisher
    ..001). REG3? is a plasma biomarker of GI GVHD that can be combined with clinical stage and histologic grade to improve risk stratification of patients...
  11. Li C, Wu X, Feng X, He Y, Liu H, Pei F, et al. A novel conditioning regimen improves outcomes in ?-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation. Blood. 2012;120:3875-81 pubmed publisher
    ..7% in the UD-PBSCT group and 10.0% in the MSD-HSCT group. In conclusion, UD-PBSCTs using the well-tolerated NF-08-TM protocol show similar results to MSD-HSCTs and can be used to treat ?-thalassemia patients in the absence of MSDs...
  12. Castor M, Rezende B, Resende C, Bernardes P, Cisalpino D, Vieira A, et al. Platelet-activating factor receptor plays a role in the pathogenesis of graft-versus-host disease by regulating leukocyte recruitment, tissue injury, and lethality. J Leukoc Biol. 2012;91:629-39 pubmed publisher
    ..PAFR antagonist may potentially be useful in the treatment of GVHD in bone marrow-transplanted patients...
  13. Sengsayadeth S, Srivastava S, Jagasia M, Savani B. Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:1479-87 pubmed publisher
    ..Therapeutic trials continue to be needed for this orphan disease...
  14. Martin P, Rizzo J, Wingard J, Ballen K, Curtin P, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18:1150-63 pubmed publisher
    ..Because the literature provides little basis for a definitive guideline, this review also provides a framework for the interpretation of previous results and the design of future studies...
  15. Klamer G, Shen S, Song E, Rice A, Knight R, Lindeman R, et al. GSK3 inhibition prevents lethal GVHD in mice. Exp Hematol. 2013;41:39-55.e10 pubmed publisher
    ..These data demonstrate that inhibition of glycogen synthase kinase 3 can potentially abrogate GVHD without compromising the efficacy of transplantation...
  16. Littera R, Orrù N, Caocci G, Sanna M, Mulargia M, Piras E, et al. Interactions between killer immunoglobulin-like receptors and their human leucocyte antigen Class I ligands influence the outcome of unrelated haematopoietic stem cell transplantation for thalassaemia: a novel predictive algorithm. Br J Haematol. 2012;156:118-28 pubmed publisher
    ..In clinical practice, this predictive tool could serve as an important supplement to clinical judgement and decision-making...
  17. Ban Y, Ogawa Y, Ibrahim O, Tatematsu Y, Kamoi M, Uchino M, et al. Morphologic evaluation of meibomian glands in chronic graft-versus-host disease using in vivo laser confocal microscopy. Mol Vis. 2011;17:2533-43 pubmed
    ..To evaluate the morphological changes of the meibomian glands (MGs) using in vivo laser confocal microscopy (CM) in dry eye (DE) patients with chronic graft-versus-host disease (cGVHD)...
  18. Liu Y, Lu P, Hsiao H, Chang C, Liu T, Yang W, et al. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus. Ann Hematol. 2012;91:587-95 pubmed publisher
    ..No clinically significant HBV reactivation was found, and the underlying HBV infection in donors or recipients before allo-HSCT did not increase the risk of CMV infection and CMV disease and did not influence survival after allo-HSCT...
  19. Pidala J. Graft-vs-host disease following allogeneic hematopoietic cell transplantation. Cancer Control. 2011;18:268-76 pubmed
  20. Lee J, Joo Y, Kim H, Ryoo H, Kim M, Lee G, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol. 2013;31:701-9 pubmed publisher
    ..We conducted a phase III randomized clinical trial to compare two myeloablative conditioning regimens for allogeneic hematopoietic cell transplantation (HCT) in patients with leukemia and myelodysplastic syndrome...
  21. Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol. 2012;67:1-8 pubmed publisher
  22. Xuan L, Huang F, Fan Z, Zhou H, Zhang X, Yu G, et al. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. J Hematol Oncol. 2012;5:46 pubmed publisher
    ..To explore whether intensified conditioning affected Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections, 185 patients undergoing allo-HSCT were enrolled...
  23. Fulton L, Carlson M, COGHILL J, Ott L, West M, Panoskaltsis Mortari A, et al. Attenuation of acute graft-versus-host disease in the absence of the transcription factor ROR?t. J Immunol. 2012;189:1765-72 pubmed publisher
    ..Thus, CD4(+) T cell expression of RORC is important in the pathogenesis of acute GVHD...
  24. Resende R, Correia Silva J, Silva T, Xavier S, Bittencourt H, Gomez R, et al. Saliva and blood interferon gamma levels and IFNG genotypes in acute graft-versus-host disease. Oral Dis. 2012;18:816-22 pubmed publisher
    ..This study aimed to investigate the association between IFN-? levels in saliva, blood, and IFNG polymorphisms, as well as the occurrence of acute graft-versus-host disease in allogenic HSCT...
  25. Ram R, Storer B, Mielcarek M, Sandmaier B, Maloney D, Martin P, et al. Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:414-22 pubmed publisher
    ..We conclude that higher cyclosporine concentrations relatively early after nonmyeloablative HCT confer protection against aGVHD that translates into reduced risks of nonrelapse and overall mortality...
  26. Kawano Y, Kim H, Matsuoka K, Bascug G, McDonough S, Ho V, et al. Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood. 2011;118:5021-30 pubmed publisher
    ..These results suggest that failure to activate Treg telomerase may restrict proliferative capacity and increase apoptotic susceptibility, resulting in the loss of peripheral tolerance and the development of cGVHD...
  27. Pavletic S, Fowler D. Are we making progress in GVHD prophylaxis and treatment?. Hematology Am Soc Hematol Educ Program. 2012;2012:251-64 pubmed publisher
  28. Zhang Y, Hosaka N, Cui Y, Shi M, Li M, Li Q, et al. Effects of intrabone marrow-bone marrow transplantation plus adult thymus transplantation on survival of mice bearing leukemia. Stem Cells Dev. 2012;21:1441-8 pubmed publisher
    ..These results suggest that IBM-BMT+ATT is effective in the treatment of leukemia with strong graft versus leukemia without increased risk of GVHD...
  29. Leventhal J, Miller J, Abecassis M, Tollerud D, Ildstad S. Evolving approaches of hematopoietic stem cell-based therapies to induce tolerance to organ transplants: the long road to tolerance. Clin Pharmacol Ther. 2013;93:36-45 pubmed publisher
    ..This review presents a historic perspective of the quest for tolerance in organ transplantation, highlighting current clinical approaches...
  30. Toubert A, Glauzy S, Douay C, Clave E. Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: never say never again. Tissue Antigens. 2012;79:83-9 pubmed publisher
    ..Thymic tissue is plastic and it is a future challenge to halt or reverse thymic GVHD therapeutically by acting at the level of T-cell progenitors generation, thymic homing and/or epithelial thymic tissue preservation...
  31. Toze C, Dalal C, Nevill T, Gillan T, Abou Mourad Y, Barnett M, et al. Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. Br J Haematol. 2012;158:174-185 pubmed publisher
    ..Results from this province-wide, two-decade cohort demonstrated that a substantial proportion of patients with high-risk CLL become long term disease-free survivors...
  32. Levine J, Paczesny S, Sarantopoulos S. Clinical applications for biomarkers of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2012;18:S116-24 pubmed publisher
    ..The utility of GVHD biomarkers in clinical care of allogeneic hematopoietic cell transplantation recipients needs to be proven through clinical trials, and potential approaches to trial design are discussed...
  33. Guo M, Hu K, Liu G, Yu C, Qiao J, Sun Q, et al. HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up. J Clin Oncol. 2012;30:4084-90 pubmed publisher
    ..Whether HLA-mismatched stem-cell microtransplantation as a novel postremission therapy in these patients will improve survival and avoid graft-versus-host disease (GVHD) is still unknown...
  34. Chen Y, McDonough S, Chen H, Kennedy J, Illiano C, Attar E, et al. Expression of ?4?7 integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHD. Bone Marrow Transplant. 2013;48:598-603 pubmed publisher
    ..44% and 1.85%), P=0.03. No differences were found in ?4?7 expression in any CD4(+) T-cell subsets or naive CD8(+) T cells. This study adds to the evidence that ?4?7 integrin is involved in lymphocyte trafficking in acute intestinal GVHD...
  35. Serody J, Hill G. The IL-17 differentiation pathway and its role in transplant outcome. Biol Blood Marrow Transplant. 2012;18:S56-61 pubmed publisher
    ..Here we discuss the IL-17 pathway of T cell differentiation and the accumulating evidence suggesting it represents an important new target for the control of deleterious alloimmune responses...
  36. Jenq R, Ubeda C, Taur Y, Menezes C, Khanin R, Dudakov J, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 2012;209:903-11 pubmed publisher
    ..Together, these data demonstrate regulation of flora by intestinal inflammation and suggest that flora manipulation may reduce intestinal inflammation and improve outcomes for allogeneic BMT recipients...
  37. Veerapathran A, Pidala J, Beato F, Yu X, Anasetti C. Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. Blood. 2011;118:5671-80 pubmed publisher
  38. Reshef R, Luger S, Hexner E, Loren A, Frey N, Nasta S, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med. 2012;367:135-45 pubmed publisher
    ..The chemokine receptor CCR5 appears to play a role in alloreactivity. We tested whether CCR5 blockade would be safe and limit GVHD in humans...
  39. Betts B, St Angelo E, Kennedy M, Young J. Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses. Blood. 2011;118:5340-3 pubmed publisher
    ..These findings merit attention in any clinical trials of tocilizumab for GVHD prevention or treatment and provide a rationale for evaluating more specific inhibitors of downstream JAK2/STAT3 signaling as well...
  40. Lv M, Huang X. Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go. J Hematol Oncol. 2012;5:10 pubmed publisher
    ..This review will describe the current situation and provide a prospective of these unique aspects of Allo-HSCT in China...
  41. Hymes S, Alousi A, Cowen E. Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease. J Am Acad Dermatol. 2012;66:535.e1-16; quiz 551-2 pubmed publisher
    ..In this section, we will provide an outline for the role of the dermatologist in a multispecialty approach to caring for patients with GVHD...
  42. Paczesny S. Discovery and validation of graft-versus-host disease biomarkers. Blood. 2013;121:585-94 pubmed publisher
    ..This review identifies biomarkers for detecting GVHD, summarizes current information on aGVHD biomarkers, proposes future prospects for the blinded evaluation of these biomarkers, and discusses the need for biomarkers of chronic GVHD...
  43. Scandling J, Busque S, Dejbakhsh Jones S, Benike C, Sarwal M, Millan M, et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant. 2012;12:1133-45 pubmed publisher
    ..All 16 patients had excellent graft function at the last observation point with or without maintenance drugs...
  44. Wolf D, von Lilienfeld Toal M, Wolf A, Schleuning M, von Bergwelt Baildon M, Held S, et al. Novel treatment concepts for graft-versus-host disease. Blood. 2012;119:16-25 pubmed publisher
    ..This review describes novel developments in the treatment of steroid-refractory GVHD, with a special focus on the rationale behind promising pharmacologic compounds or up-coming cellular therapies...
  45. He S, Wang J, Kato K, Xie F, Varambally S, Mineishi S, et al. Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. Blood. 2012;119:1274-82 pubmed publisher
    ..Our findings indicate that modulation of histone methylation may have significant implications in the development of novel approaches to treat ongoing GVHD and other T cell-mediated inflammatory disorders in a broad context...
  46. Miyagawa F, Zhang H, Terunuma A, Ozato K, Tagaya Y, Katz S. Interferon regulatory factor 8 integrates T-cell receptor and cytokine-signaling pathways and drives effector differentiation of CD8 T cells. Proc Natl Acad Sci U S A. 2012;109:12123-8 pubmed publisher
  47. Young J, Wu T, Chen Y, Zhao D, Liu H, Yi T, et al. Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease. J Immunol. 2012;189:222-33 pubmed publisher
    ..Therefore, a major mechanism whereby donor B cells augment cGVHD is through augmenting the clonal expansion, differentiation, and survival of pathogenic CD4(+) T cells...
  48. Yuksekkaya H, Arikan C, Tumgor G, Aksoylar S, Kilic M, Aydogdu S. Late-onset graft-versus-host disease after pediatric living-related liver transplantation for Langerhans cell histiocytosis. Pediatr Transplant. 2011;15:E105-9 pubmed publisher
    ..GVHD after OLT should be keep in mind in patients with rash and BM suppression after liver transplantation. In LDLT, a patient who carries risk factors should investigated for optimal HLA matching...
  49. Dignan F, Clark A, Amrolia P, Cornish J, Jackson G, Mahendra P, et al. Diagnosis and management of acute graft-versus-host disease. Br J Haematol. 2012;158:30-45 pubmed publisher
    ..The goal of treatment should be effective control of graft-versus-host disease while minimizing risk of toxicity and relapse...
  50. Jacobs R, Tran U, Chen H, Kassim A, Engelhardt B, Greer J, et al. Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria. Bone Marrow Transplant. 2012;47:1470-3 pubmed publisher
    ..Early diagnosis and preventive strategies in high-risk populations need to be studied in clinical trials to prevent devastating impact on quality of life in patients with prolonged ocular GVHD...
  51. Cutler C, Kim H, Sun L, Sese D, Glotzbecker B, Armand P, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011;118:6691-7 pubmed publisher
    ..0%, P = .04). We conclude that identification of preformed DSAs in umbilical cord blood recipients should be performed and that the use of umbilical cord blood units where preformed host DSAs exist should be avoided...
  52. Levine J, Logan B, Wu J, Alousi A, Bolaños Meade J, Ferrara J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood. 2012;119:3854-60 pubmed publisher
    ..The study was registered in clinicaltrials.gov as NCT00224874. ..
  53. Harris A, Ferrara J, Braun T, Holler E, Teshima T, Levine J, et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood. 2012;119:2960-3 pubmed publisher
    ..02, respectively). Liver GVHD without GI involvement at GVHD onset and non-GVHD liver complications were uncommon; all 3 biomarkers were elevated in liver GVHD, but did not distinguish GVHD from other causes of hyperbilirubinemia...
  54. Ali N, Flutter B, Sanchez Rodriguez R, Sharif Paghaleh E, Barber L, Lombardi G, et al. Xenogeneic graft-versus-host-disease in NOD-scid IL-2R?null mice display a T-effector memory phenotype. PLoS ONE. 2012;7:e44219 pubmed publisher
    ..Characterization of Hu-PBMC mice provides a strong preclinical platform for the application of novel immunotherapies targeting T(EM)-cell driven GvHD...
  55. Chen X, Yang J, Xu M, Wen T, Yan L. Unsuccessful treatment of four patients with acute graft-vs-host disease after liver transplantation. World J Gastroenterol. 2012;18:84-9 pubmed publisher
    ..To investigate appropriate therapeutic strategies for graft-vs-host disease (GVHD) following liver transplantation...
  56. Sela U, Olds P, Park A, Schlesinger S, Steinman R. Dendritic cells induce antigen-specific regulatory T cells that prevent graft versus host disease and persist in mice. J Exp Med. 2011;208:2489-96 pubmed publisher
    ..These results indicate that induced Foxp3(+) T reg cells, after proliferating and differentiating into antigen-specific suppressive T cells, can persist for long periods while suppressing a powerful inflammatory disease...
  57. Pan B, Zeng L, Cheng H, Song G, Chen C, Zhang Y, et al. Altered balance between Th1 and Th17 cells in circulation is an indicator for the severity of murine acute GVHD. Immunol Lett. 2012;142:48-54 pubmed publisher
    ..We describe the changing proportions of Th1 and Th17 cells in acute GVHD, and we find that Th1/Th17 ratio is an accurate indicator for predicting the severity of acute GVHD...
  58. Toubai T, Tanaka J, Paczesny S, Shono Y, Reddy P, Imamura M. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)?. Curr Stem Cell Res Ther. 2012;7:229-39 pubmed
    ..In this review, we summarize the roles of individual cytokines in the pathophysiology of acute GVHD and discuss the possibility of cytokines as biomarkers of acute GVHD after allo-HCT...
  59. Ersvær E, Melve G, Bruserud O. Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation?. Cancer Immunol Immunother. 2011;60:1669-81 pubmed publisher
    ..In the present article, we review previous studies of Th17 cells in AML and in the development of GVHD, possible therapeutic strategies and available therapeutic tools for targeting of Th17 cells...
  60. Fowler D, Mossoba M, Steinberg S, Halverson D, Stroncek D, Khuu H, et al. Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood. 2013;121:2864-74 pubmed publisher
    ..These results demonstrate the safety of this low-intensity transplant approach and the feasibility of subsequent randomized studies to compare T-Rapa cell-based therapy with standard transplantation regimens...
  61. Qian L, Mei K, Shen J, Cai J. Administration of hydrogen-rich saline protects mice from lethal acute graft-versus-host disease (aGVHD). Transplantation. 2013;95:658-62 pubmed publisher
    ..Therefore, we hypothesized that hydrogen may have therapeutic effects on aGVHD...
  62. Tsukamoto H, Chernogorova P, Ayata K, Gerlach U, Rughani A, Ritchey J, et al. Deficiency of CD73/ecto-5'-nucleotidase in mice enhances acute graft-versus-host disease. Blood. 2012;119:4554-64 pubmed publisher